Skip to main content

Newly Public Rosetta Genomics Says Q4 R&D Rises 30 Percent; No Revenue Yet

NEW YORK (GenomeWeb News) — Rosetta Genomics today released its first earnings statement as a new public company, saying it generated no revenues in the fourth quarter, R&D spending increased 30 percentl, and net losses increased 16 percent.
 
R&D spending for the three months ended Dec. 31, 2006, increased to $1.3 million from $1 million in the year-ago period.
 
The company said net loss increased to $2.1 million from $1.8 million in the fourth quarter of 2005.
 
Rosetta, which went public last month, said it had around $5.2 million in cash and equivalents as of Dec. 31.
 
The company said it is collaborating with Isis pharmaceuticals for a micro-RNA-based therapeutic for liver cancer, and said it has agreements in place with Max-Planck-Innovation, the Rockefeller University and Johns Hopkins University.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.